Prediction: Rocket Lab's Revenue Tops $1.5 Billion in 2027 Without Counting Iridium

Rocket Lab reported record Q2 2026 revenue of $234 million, up 62% year over year, with backlog rising 137% to $2.36 billion; management guided Q3 revenue to $250 million-$265 million. The article projects standalone 2027 revenue above $1.5 billion, excluding the pending $8 billion Iridium acquisition expected to close in mid-2027, supported by roughly $1.1 billion of backlog scheduled for revenue recognition within 12 months. Risks include potential execution delays, a Q3 adjusted EBITDA loss of $17 million-$23 million versus an $8.8 million Q2 loss, and a valuation near $63 per share that already reflects substantial growth.

Analysis

The key underwriting error is treating the near-term conversion bucket as incremental 2027 visibility: it spans late 2026 through mid-2027, so only a portion supports the 2027 revenue target. The residual requirement is therefore materially larger than the simple backlog math suggests and depends on continued bookings, manufacturing throughput, and acceptance timing. This raises the sensitivity of the equity to quarterly book-to-bill and delivery cadence rather than reported revenue alone.

Revenue growth is not yet translating into operating leverage; incremental engineering, factory, and launch-development spending can keep EBITDA losses widening even as sales scale. For RKLB, the next multiple-setting metric is gross-margin and EBITDA-loss progression, not another revenue beat: a growth stock priced for multi-year execution is vulnerable to sharp compression if cash burn rises or the space-systems mix carries lower-than-expected program margins.

The pending IRDM transaction creates a separate capital-allocation overhang. If funded materially with RKLB equity, dilution can cap upside before closing; if debt-funded, the market will focus on leverage, interest burden, and whether stable service revenue offsets integration and refinancing risk. Neutron remains asymmetric: a credible test and launch schedule can rerate RKLB as a launch-platform challenger over 6-18 months, while a schedule slip is likely more damaging than the article implies because it would challenge management's execution premium even if near-term satellite revenue remains intact.

Key Decisions for Investors

• Do not add outright RKLB exposure into the next earnings release; wait for evidence that quarterly bookings exceed revenue and that EBITDA loss narrows sequentially. A revenue beat without margin or cash-burn improvement is a sell-the-news setup over the following 1-3 months.
• Use RKLB as a tactical short or put-spread candidate only after a failed earnings/guidance catalyst: trigger on reduced 2027 delivery visibility, weaker bookings, or a wider EBITDA-loss outlook. The thesis is falsified by sustained positive book-to-bill, improving gross margin, and a firm Neutron launch-date commitment.
• Establish an IRDM merger-arbitrage watchlist rather than a position until consideration mix, financing commitments, termination provisions, and regulatory timetable are disclosed. A long IRDM / short RKLB hedge could be attractive if the target trades at a wide deal spread and stock consideration leaves the pair naturally hedged; absent those terms, risk/reward cannot be sized responsibly.
• Monitor RKLB's Neutron pad-readiness milestone in Q4 2026 as a 6-18 month upside catalyst. A demonstrable on-schedule milestone supports a selective long entry after any execution-driven pullback; a delay should be treated as a reason to reduce exposure because it weakens the strategic-launch optionality embedded in valuation.